Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Rylo Health vs StackMD

Rylo Health
Graded #240

Higher grade

vs+1.3000000000000043
StackMD
Graded #259

Lower grade

The verdict

Rylo Health takes it — 64.7/100 to 63.4/100, but only just.

Rylo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Texas-prescriber telehealth selling compounded semaglutide and tirzepatide alongside a peptide line, naming both its medical group and its dispensing pharmacy. StackMD is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRylo Health +18
64
46
Dose & formulationRylo Health +10
64
54
Clinical oversightStackMD +3
75
78
Labs & monitoringStackMD +9
53
62
FulfillmentStackMD +6
83
89
Contract termsStackMD +32
37
69
Rylo Health · left barStackMD · right bar

The numbers

MetricRylo HealthStackMD
WeighScore64.7/10063.4/100
GradeCC
Scorecard rank#240#259
Semaglutide$149/mo (promotional rate, compounded)$125/mo (1 mg dose, plus a separate fee, compounded)
Tirzepatide$249/mo (compounded)$199/mo (5 mg dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Rylo Health

Graded #240 · C

Strengths

  • Names its dispensing pharmacy in full, with address and phone: VialsRX in Houston, Texas
  • Names its medical group, Lone Star Virtual Health PLLC, and gives a provider contact
  • Standard prices published openly alongside the promotional rate, so the real ongoing cost is visible
  • Cancel in one click from the patient portal, with no contracts and no cancellation fees
  • Peptide line priced openly, including NAD+ and sermorelin

Where it loses points

  • Headline $100 and $160 rates are limited to the first 20 patients; standard rates are $149 and $249
  • No LegitScript certification is claimed or displayed
  • Several peptide products are advertised as coming soon rather than available
  • No published refund policy beyond the no-cancellation-fee statement
StackMD

Graded #259 · C

Strengths

  • Publishes an exact price for every dose strength rather than a single 'from' figure — semaglutide $125-$225, tirzepatide $199-$449
  • Names both its legal entity (Medical 360 HC PLLC) and its prescribing telehealth partner, SamaritanMD
  • No membership or platform fee — the medication price is the whole price
  • States plainly that its compounded medications are 'not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Telehealth offered in all 50 states per its terms, with free discreet shipping and FSA/HSA eligibility

Where it loses points

  • All sales are final — 'No refunds are issued except as described below', and dispensed medication cannot be returned
  • Compounding pharmacies are never named, only 'a licensed third-party pharmacy'
  • Price rises steeply with dose: tirzepatide runs $199 at 5mg to $449 at 30mg
  • Billing and refunds are handled by SamaritanMD — StackMD 'has no authority to issue refunds' on its behalf
  • Terms impose binding arbitration in New York and waive jury trial and class-action participation

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard